Skip to main content

Table 1 Patient and disease characteristics (ITT population)

From: Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs. intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial

  Sequence A (n = 175) Sequence B (n = 164) Total (n = 339)
Age in years, mean ± SD 61.9 ± 8.8 62.7 ± 9.2 62.3 ± 9.0
Female gender, % 38.3 40.9 39.5
Weight in kg, mean ± SD 90.1 ± 15.8 91.1 ± 15.1 90.5 ± 15.5
BMI in kg/m2, mean ± SD 30.9 ± 4.5 31.2 ± 4.7 31.0 ± 4.6
WC in cm, mean ± SD 106.4 ± 11.7 107.2 ± 11.4 106.8 ± 11.5
Diabetes duration in months, mean ± SD 115.1 ± 71.3 115.2 ± 71.0 115.2 ± 71.0
Diabetes duration in years, mean ± SD 9.6 ± 5.9 9.6 ± 5.9 9.6 ± 5.9
HbA1c in %, mean ± SD 8.17 ± 0.73 8.13 ± 0.72 8.15 ± 0.72
FBG in mmol/L, mean ± SD 9.24 ± 2.23 9.50 ± 2.16 9.37 ± 2.19
Time since first OHA treatment in months, mean ± SD 72.8 ± 62.2 67.3 ± 55.3 70.2 ± 58.9
Concomitant disease    
Cardiac disorders, % 28.0 23.8 26.0
Vascular disorders, % 86.3 88.4 87.3
Renal and urinary disorders, % 24.6 18.3 21.5
Concomitant oral medication    
Metformin, % 90.9 89.6 90.3
Sulfonylurea, % 57.7 54.9 56.3
DPP-IV inhibitors, % 22.3 26.2 24.2
  1. Legend: Sequence A: starting with insulin glargine and then switching to NPH insulin; Sequence B: starting with NPH insulin and then switching to insulin glargine; SD, standard deviation; BMI, body mass index; WC, waist circumference; OHA, oral hypoglycemic agents; FBG, fasting blood glucose